Skip to main content
. Author manuscript; available in PMC: 2013 Jun 27.
Published in final edited form as: Leuk Lymphoma. 2009 Mar;50(3):349–356. doi: 10.1080/10428190902730227

Figure 2.

Figure 2

Decline in CD3/CD4-positive T-cell subsets after one cycle of clofarabine. Four-colour flow cytometry with directly conjugated antibodies for CD3 and CD4 performed prior to clofarabine therapy, on day 5 of cycle 1, and immediately prior to the start of cycle 2 demonstrates a 78.9% (range 62.0–88.7%) median decline in absolute CD3/CD4+ T-cells. Samples were available at all three time points (pre-treatment, day 5 of cycle 1 and prior to cycle 2) in patients 1, 3–6 and from two time points (pre-treatment and day 5) in patient 2.